PHILADELPHIA, PA 10 August 2010 – ERT, a
leading provider of centralized services to global pharmaceutical,
biotechnology and medical device companies, announces that Joel
Morganroth, MD, Chairman and Chief Scientist, has been acknowledged
by PharmaVOICE magazine as one of the 100 most inspiring people in
the life sciences industry. Dr. Morganroth has been recognized for
his lifetime contribution to the advancement of individuals and
science and the welfare of patients. The PharmaVOICE 100 winners
are nominated by the magazine’s readers, who identify the
individuals they consider to have the greatest influence and
positive impact on corporate leadership, research and development,
technology, creativity, marketing and business strategies.
“I am especially honored to have been nominated to receive
this prestigious award,” Dr. Morganroth stated. “This
recognition would not have been possible had I not been part of
such an innovative company and competent team of experts, committed
to redefining how clinical trials can be successfully conducted to
allow for quick and accurate product development
decisions.”
Dr. Joel Morganroth
Dr. Morganroth was nominated for the PharmaVOICE 100 award based
on his outstanding career in the life sciences industry spanning
more than 30 years and his ability to inspire and motivate his
colleagues. With a vision for innovation, he invented ERT’s
breakthrough and proprietary EXPERT® technology platform for
centralized electronic electrocardiograph data collection and
management. As the leader of ERT’s world-renowned cardiology
team, Dr. Morganroth provides comprehensive, strategic consultation
on medical and regulatory cardiac safety issues. Having served as a
consultant for the US FDA and regulatory authorities in Canada and
Europe for many years, he has helped ERT to develop new solutions
for assessing cardiac safety of new drugs in compliance with
worldwide legislation with the ultimate aim of safeguarding human
health.
Dr. Morganroth has contributed to the advancement of individuals
and science in a number of different roles, from faculty, special
government and consultant positions to memberships in major
cardiology organizations. He has co-authored more than 350 articles
and 24 books, he has been featured in different “Who’s
Who” listings, and has received a Special Citation award from
the FDA Commissioner for his work in providing invaluable
assistance to the FDA for the development of a format for
regulatory submission of digital annotated electrocardiograms
(ECGs) to determine the cardiac safety of new drugs.
Dr. Michael McKelvey, Chief Executive Officer of ERT, comments:
“A globally recognized cardiologist and clinical researcher,
Dr. Morganroth has been instrumental in defining the opportunity in
cardiac safety that has shaped the direction of ERT beginning in
the late 1970s. He has managed to successfully define an innovative
set of processes and technologies that have helped lead ERT to its
position as the clinical trial research industry’s largest
Cardiac Safety services company. Being named one of the 100 most
inspiring people in the life sciences industry is in recognition of
his exceptional career and a great honor for ERT as
well.”
For further information on ERT and its technology and services,
please email info@ert.com,
call +1 215 972 0420 or visit www.ert.com.
For further press information, please contact Fiona Robinson,
The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel,
Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44
1477 539540, email ert@scottpr.com.
About ERT
Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries. The Company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG)
technology and services to evaluate cardiac safety in clinical
development. It is also a leading provider of centralized
respiratory technology and services to evaluate pulmonary function
efficacy and safety in clinical development. Sponsors can further
use the Company’s solutions to streamline the clinical trials
process by automating the collection, analysis, and distribution of
ePRO clinical data using multi-mode technology in all phases of
clinical development as well as selected medical devices for the
clinical trials and healthcare industries.
Statements included in this release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve a
number of risks and uncertainties, which could cause actual results
to differ materially from those expressed or implied from such
statements. These risks and uncertainties include, without
limitation, the Company’s ability to obtain new contracts,
variability in size, scope, and duration of projects, integration
of acquisitions, competitive factors, technological development,
market demand, and other factors described in the Company’s
filings with the Securities and Exchange Commission. The
Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contacts:
Fiona Robinson
The Scott Partnership
Tel: +44 1477 539539
John Blakeley
ERT
+1 215 972 0420
